Find Bimatoprost Grenod manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1194396-71-8, Ncx 470, Bimatoprost grenod, [(e,3s)-1-[(1r,2r,3s,5r)-2-[(z)-7-(ethylamino)-7-oxohept-2-enyl]-3,5-dihydroxycyclopentyl]-5-phenylpent-1-en-3-yl] 6-nitrooxyhexanoate, Bimatoprost grenod (usan), Bimatoprost grenod [usan]
Molecular Formula
C31H46N2O8
Molecular Weight
574.7  g/mol
InChI Key
NTQMJNDRYSYWNJ-BPXWCPHMSA-N
FDA UNII
QP51BE89NE

6-(nitrooxy)-hexanoic acid, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester
1 2D Structure

6-(nitrooxy)-hexanoic acid, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(E,3S)-1-[(1R,2R,3S,5R)-2-[(Z)-7-(ethylamino)-7-oxohept-2-enyl]-3,5-dihydroxycyclopentyl]-5-phenylpent-1-en-3-yl] 6-nitrooxyhexanoate
2.1.2 InChI
InChI=1S/C31H46N2O8/c1-2-32-30(36)16-10-4-3-9-15-26-27(29(35)23-28(26)34)21-20-25(19-18-24-13-7-5-8-14-24)41-31(37)17-11-6-12-22-40-33(38)39/h3,5,7-9,13-14,20-21,25-29,34-35H,2,4,6,10-12,15-19,22-23H2,1H3,(H,32,36)/b9-3-,21-20+/t25-,26+,27+,28-,29+/m0/s1
2.1.3 InChI Key
NTQMJNDRYSYWNJ-BPXWCPHMSA-N
2.2 Other Identifiers
2.2.1 UNII
QP51BE89NE
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1194396-71-8

2. Ncx 470

3. Bimatoprost Grenod

4. [(e,3s)-1-[(1r,2r,3s,5r)-2-[(z)-7-(ethylamino)-7-oxohept-2-enyl]-3,5-dihydroxycyclopentyl]-5-phenylpent-1-en-3-yl] 6-nitrooxyhexanoate

5. Bimatoprost Grenod (usan)

6. Bimatoprost Grenod [usan]

7. Bimatoprost Grenod [inn]

8. Qp51be89ne

9. Schembl397725

10. C31h46n2o8

11. Akos040755517

12. Da-56065

13. Ms-30350

14. Hy-139419

15. Cs-0200448

16. D12599

17. 15-(6-nitroxyhexanoyl)-17-phenyl Trinor Prostaglandin F2??

18. (s,e)-1-((1r,2r,3s,5r)-2-((z)-7-(ethylamino)-7-oxohept-2-en-1-yl)-3,5-dihydroxycyclopentyl)-5-phenylpent-1-en-3-yl 6-(nitrooxy)hexanoate

19. [(e,1s)-3-[(1r,2r,3s,5r)-2-[(z)-7-(ethylamino)-7-oxo-hept-2-enyl]-3,5-dihydroxy-cyclopentyl]-1-(2-phenylethyl)allyl] 6-nitrooxyhexanoate

20. Hexanoic Acid, 6-(nitrooxy)-, (1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl Ester

2.4 Create Date
2009-11-23
3 Chemical and Physical Properties
Molecular Weight 574.7 g/mol
Molecular Formula C31H46N2O8
XLogP34.7
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count20
Exact Mass Da
Monoisotopic Mass Da
Topological Polar Surface Area151
Heavy Atom Count41
Formal Charge0
Complexity821
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count2
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Listed Suppliers

read-more
read-more

01

Inke S.A

Spain
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInke S.A: APIs manufacturing plant.

Flag Spain
Digital Content Digital Content

Bimatoprost Grenod

About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...

Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse therapeutic areas, but mainly for use in Respiratory. Inke has been successfully inspected by every major global authority for a wide array of products (last inspection on behalf of US-FDA was in 2023). For the last two decades, the company has made strong strides to become a prestige provider of respiratory APIs for inhalation. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Inke Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty